Ha habido 50 transacciones internas recientes registradas para Rubius Therapeutics, Inc. (RUBY), incluyendo 32 compras y 15 ventas. El total de compras internas fue valorado en $7.01M y el total de ventas internas en $2.46M.
Internos destacados con actividad reciente incluyen Appelhans Dannielle, Cagnoni Pablo J, Turka Laurence A.. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.
Operaciones de Insiders — RUBY
| Fecha |
Nombre |
Cargo |
Tipo de Transacción |
Acciones |
Precio Promedio |
Valor |
Acciones en Propiedad |
| 2023-02-24 |
Appelhans Dannielle |
CEO and President |
Venta Informativa |
10,385 |
$0.13 |
$1.32K |
- |
| 2023-02-01 |
Cagnoni Pablo J |
Director |
Venta Informativa |
8,448 |
$0.25 |
$2.11K |
66,082 |
| 2023-02-01 |
Appelhans Dannielle |
CEO and President |
Venta Informativa |
3,878 |
$0.25 |
$969.50 |
10,385 |
| 2023-01-31 |
Cagnoni Pablo J |
Director |
Venta Informativa |
7,240 |
$0.24 |
$1.74K |
74,530 |
| 2023-01-31 |
Turka Laurence A. |
Chief Scientific Officer |
Venta Informativa |
2,593 |
$0.24 |
$622.32 |
18,391 |
| 2023-01-31 |
Appelhans Dannielle |
CEO and President |
Ejercicio de Opciones |
7,500 |
- |
- |
14,263 |
| 2023-01-29 |
Cagnoni Pablo J |
Director |
Ejercicio de Opciones (Venta) |
21,250 |
- |
- |
42,500 |
| 2023-01-29 |
Turka Laurence A. |
Chief Scientific Officer |
Ejercicio de Opciones |
7,438 |
- |
- |
12,359 |
| 2022-08-09 |
Appelhans Dannielle |
Chief Operating Officer |
Venta Informativa |
5,737 |
$0.80 |
$4.59K |
6,763 |
| 2022-07-29 |
Schaffert Susanne |
Director |
Concesión de RSU |
50,000 |
- |
- |
50,000 |
| 2022-07-12 |
Schaffert Susanne |
Director |
Desconocido |
- |
- |
- |
- |
| 2022-05-12 |
Afeyan Noubar |
10 Percent Owner |
Concesión de RSU |
25,000 |
$1.24 |
$31K |
25,000 |
| 2022-05-12 |
Epstein David R |
Director |
Concesión de RSU |
499,762 |
- |
- |
499,762 |
| 2022-05-12 |
Rosenblatt Michael |
Director |
Concesión de RSU |
25,000 |
$1.24 |
$31K |
25,000 |
| 2022-05-12 |
Cuss Francis M |
Director |
Concesión de RSU |
25,000 |
$1.24 |
$31K |
25,000 |
| 2022-05-12 |
Sohn Catherine A. |
Director |
Concesión de RSU |
25,000 |
$1.24 |
$31K |
25,000 |
| 2022-05-12 |
Holles Natalie C. |
Director |
Concesión de RSU |
25,000 |
$1.24 |
$31K |
25,000 |
| 2022-05-12 |
Symonds Jonathan |
Director |
Concesión de RSU |
25,000 |
$1.24 |
$31K |
25,000 |
| 2022-05-12 |
Prener Anne |
Director |
Concesión de RSU |
25,000 |
$1.24 |
$31K |
25,000 |
| 2022-04-21 |
Epstein David R |
Director |
Compra Informativa |
30,000 |
$1.44 |
$43.33K |
4,720,012 |
| 2022-02-01 |
Cagnoni Pablo J |
CEO and President |
Venta Informativa |
6,730 |
$6.57 |
$44.24K |
35,520 |
| 2022-02-01 |
Keson-brookes Maiken |
CLO & Corp. Secretary |
Venta Informativa |
2,732 |
$6.57 |
$17.96K |
5,343 |
| 2022-02-01 |
Turka Laurence A. |
Chief Scientific Officer |
Venta Informativa |
2,517 |
$6.57 |
$16.54K |
4,921 |
| 2022-01-31 |
Cagnoni Pablo J |
CEO and President |
Concesión de RSU |
100,000 |
- |
- |
100,000 |
| 2022-01-31 |
Carmona Jose |
Chief Financial Officer |
Concesión de RSU |
34,500 |
- |
- |
34,500 |
| 2022-01-31 |
Keson-brookes Maiken |
CLO & Corp. Secretary |
Concesión de RSU |
34,500 |
- |
- |
34,500 |
| 2022-01-31 |
Turka Laurence A. |
Chief Scientific Officer |
Concesión de RSU |
34,500 |
- |
- |
34,500 |
| 2022-01-31 |
Appelhans Dannielle |
Chief Operating Officer |
Concesión de RSU |
30,000 |
- |
- |
30,000 |
| 2022-01-29 |
Cagnoni Pablo J |
CEO and President |
Ejercicio de Opciones |
21,250 |
- |
- |
42,250 |
| 2022-01-29 |
Keson-brookes Maiken |
CLO & Corp. Secretary |
Ejercicio de Opciones |
8,075 |
- |
- |
8,075 |
| 2022-01-29 |
Turka Laurence A. |
Chief Scientific Officer |
Ejercicio de Opciones |
7,438 |
- |
- |
7,438 |
| 2021-12-31 |
Cagnoni Pablo J |
CEO and President |
Desconocido |
- |
- |
- |
- |
| 2021-08-31 |
Appelhans Dannielle |
Chief Operating Officer |
Concesión de RSU |
50,000 |
- |
- |
50,000 |
| 2021-08-09 |
Appelhans Dannielle |
Officer |
Desconocido |
- |
- |
- |
- |
| 2021-05-12 |
Afeyan Noubar |
10 Percent Owner |
Concesión de RSU |
25,000 |
$23.25 |
$581.25K |
25,000 |
| 2021-05-12 |
Epstein David R |
Director |
Concesión de RSU |
27,919 |
$23.25 |
$649.12K |
27,919 |
| 2021-05-12 |
Rosenblatt Michael |
Director |
Concesión de RSU |
25,000 |
$23.25 |
$581.25K |
25,000 |
| 2021-05-12 |
Cuss Francis M |
Director |
Concesión de RSU |
25,000 |
$23.25 |
$581.25K |
25,000 |
| 2021-05-12 |
Sohn Catherine A. |
Director |
Concesión de RSU |
25,000 |
$23.25 |
$581.25K |
25,000 |
| 2021-05-12 |
Holles Natalie C. |
Director |
Concesión de RSU |
25,000 |
$23.25 |
$581.25K |
25,000 |
| 2021-05-12 |
Symonds Jonathan |
Director |
Concesión de RSU |
25,000 |
$23.25 |
$581.25K |
25,000 |
| 2021-05-12 |
Prener Anne |
Director |
Concesión de RSU |
25,000 |
$23.25 |
$581.25K |
25,000 |
| 2021-03-19 |
Flagship Ventures Fund Iv General Partner Llc |
10 Percent Owner |
Compra Informativa |
70,000 |
$29.00 |
$2.03M |
2,633,703 |
| 2021-03-15 |
Keson-brookes Maiken |
CLO & Corp. Secretary |
Venta Informativa |
25,000 |
$20.24 |
$505.97K |
- |
| 2021-02-11 |
Epstein David R |
Director |
Venta Informativa |
26,704 |
$14.93 |
$398.56K |
4,690,012 |
| 2021-02-10 |
Epstein David R |
Director |
Venta Informativa |
7,404 |
$14.79 |
$109.53K |
4,716,716 |
| 2021-02-09 |
Epstein David R |
Director |
Venta Informativa |
2,100 |
$14.83 |
$31.15K |
4,724,120 |
| 2021-02-08 |
Epstein David R |
Director |
Venta Informativa |
89,233 |
$14.88 |
$1.33M |
4,726,220 |
| 2021-01-29 |
Cagnoni Pablo J |
CEO and President |
Concesión de RSU |
85,000 |
- |
- |
85,000 |
| 2021-01-29 |
Keson-brookes Maiken |
CLO & Corp. Secretary |
Concesión de RSU |
32,300 |
- |
- |
32,300 |
■ Informativa — transacción en mercado abierto (más significativa)
■ No informativa (compra) — premio, ejercicio de opción, conversión
■ No informativa (venta) — retención fiscal, venta de adjudicación
■ Neutral — regalo, fideicomiso, vencimiento